RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address high unmet medical needs. We believe that we are well positioned to compete successfully using our RNAi technology platform for the development of novel therapeutics to improve patients’ lives. The Company is supported by a proven and experienced management team, an accomplished Scientific Advisory Board and an extensive intellectual property portfolio.
PROPRIETARY SELF-DELIVERING RNAi (sd-rxRNA®) TECHNOLOGY PLATFORM
Provided by Nasdaq.
Sep 5, 2018 at 3:25 PM EDT20th Annual Rodman & Renshaw Global Investment Conference
Aug 14, 2018 at 4:30 PM EDTRXi Pharmaceuticals Second Quarter 2018 Conference Call
May 16 - May 19, 2018International Investigative Dermatology (IID) Conference